/LXRX
LXRX Stock - Lexicon Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$1.17-0.85%
$0.01 (-0.85%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.58
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+412.8%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LXRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.16 – $1.18
TARGET (TP)$6.00
STOP LOSS$1.08
RISK/REWARD1:53.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.97
52W High$1.66
52W Low$0.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $31.08M | $1.20M | $139,000 | $298,000 | $24.00M |
| Gross Profit | $30.46M | $-57,768,000 | $-52,377,000 | $-54,748,000 | $22.07M |
| Gross Margin | 98.0% | -4798.0% | -37681.3% | -18371.8% | 92.0% |
| Operating Income | $-197,117,000 | $-171,750,000 | $-100,760,000 | $-87,090,000 | $-47,800,000 |
| Net Income | $-200,403,000 | $-177,119,000 | $-101,944,000 | $-87,758,000 | $-58,574,000 |
| Net Margin | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% |
| EPS | $-0.63 | $-0.80 | $-0.62 | $-0.61 | $-0.63 |
Company Overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$6
Average Target
↑ 395.7% Upside
Now
$1
Low
$6
Average
$10
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 5th 2025 | Leerink Partners | Downgrade | Market Perform | $1← $2 |
| June 17th 2024 | H.C. Wainwright | Initiation | Buy | $10 |
| April 30th 2024 | Leerink Partners | Initiation | Outperform | $5 |
| March 7th 2023 | Jefferies | Initiation | Hold | $3 |
| August 12th 2022 | Piper Sandler | Initiation | Overweight | $10 |
Earnings History & Surprises
LXRXBeat Rate
56%
Last 18 quarters
Avg Surprise
+11.3%
EPS vs Estimate
Beats / Misses
10/5
3 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
+13.0%
$-0.20vs$-0.23
Q2 24
-11.1%
$-0.20vs$-0.18
Q3 24
+5.6%
$-0.17vs$-0.18
Q4 24
-5.9%
$-0.18vs$-0.17
Q1 25
+18.2%
$-0.09vs$-0.11
Q2 25
+30.0%
$-0.07vs$-0.10
Q3 25
+112.5%
$0.01vs$-0.08
Q4 25
+42.9%
$-0.04vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.08 | $0.01 | +112.5% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.17 | $-0.22 | -29.4% | ✗ MISS |
Q2 2023 | May 2, 2023 | $-0.17 | $-0.17 | 0.0% | = MET |
Q1 2023 | Mar 2, 2023 | $-0.14 | $-0.16 | -14.3% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.15 | $-0.13 | +13.3% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-0.15 | $-0.16 | -6.7% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.16 | $-0.16 | 0.0% | = MET |
Q1 2022 | Feb 28, 2022 | $-0.17 | $-0.17 | 0.0% | = MET |
Q4 2021 | Nov 3, 2021 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Latest News
Lexicon Pharma Announces Publication Of Preclinical Data Validating Acyl-CoA Synthetase 5 As Target For Obesity And Chronic Weight Management
📈 PositiveBenzinga•Dec 10, 2025, 01:31 PM
Lexicon Pharma To Present Clinical Data On Adipose Tissue Distribution In Non-Diabetic Patients Treated With Sotagliflozin At CVCT 2025
➖ NeutralBenzinga•Dec 5, 2025, 01:36 PM
Reported Saturday, Lexicon Pharmaceuticals Data From SOTA P CARDIA Show Sotagliflozin Benefits Across Cardiac Structure Function And Functional Capacity In HFpEF Without Diabetes
📈 PositiveBenzinga•Nov 10, 2025, 09:00 AM
Lexicon Pharmaceuticals Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $14.182M Beat $4.649M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:31 PM
Lexicon Pharmaceuticals To Present Data From Three Studies Of Sotagliflozin At American Heart Association's Scientific Sessions 2025 And Hypertrophic Cardiomyopathy Society Scientific Sessions
➖ NeutralBenzinga•Nov 4, 2025, 01:34 PM
Lexicon Pharma Presents Additional Clinical Data And Program Updates From Phase 2 Pilavapadin Program At 19th Annual Pain Therapeutics Summit
➖ NeutralBenzinga•Oct 14, 2025, 12:02 PM
Lexicon Pharma Updates Zynquista NDA Resubmission Timeline As FDA Delays Feedback To Q4 Following Type D Meeting
➖ NeutralBenzinga•Sep 22, 2025, 08:02 PM
Lexicon Reports Phase 2b Results For Pilavapadin, A Potential First Non-Opioid Oral Therapy For Diabetic Nerve Pain
📈 PositiveBenzinga•Sep 17, 2025, 11:11 AM
Lexicon Pharma Presents Clinical Data For Investigational, AAK1-Inhibitor, Pilavapadin, For Treatment Of Diabetic Peripheral Neuropathic Pain At Three Upcoming Medical Meetings
➖ NeutralBenzinga•Sep 11, 2025, 12:33 PM
Lexicon Pharmaceuticals Submits New Clinical Data For Zynquista NDA Resubmission; FDA Feedback Expected By September End
📈 PositiveBenzinga•Sep 8, 2025, 12:43 PM
Lexicon Pharmaceuticals Announces It Will Present New Preclinical Data At The 9th International Congress On Neuropathic Pain 2025 ShowingThat Pilavapadin Reduces Neuropathic Pain In Models Of Chemotherapy-induced Peripheral Neuropathy And Multiple Sclerosis
📈 PositiveBenzinga•Sep 4, 2025, 12:36 PM
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target
📈 PositiveBenzinga•Sep 2, 2025, 04:09 PM
Lexicon Pharma Presents Post-Hoc Analysis "Efficacy Of Sotagliflozin Among Older Adults: A Pooled Analysis Of SCORED And SOLOIST-WHF" Of Clinical Data At ESC 2025 Congress
➖ NeutralBenzinga•Sep 2, 2025, 12:34 PM
Frequently Asked Questions about LXRX
What is LXRX's current stock price?
Lexicon Pharmaceuticals, Inc. (LXRX) is currently trading at $1.17 per share. The stock has moved -0.85% today.
What is the analyst price target for LXRX?
The average analyst price target for LXRX is $6.00, based on 1 analyst.
What sector is Lexicon Pharmaceuticals, Inc. in?
Lexicon Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LXRX's market cap?
Lexicon Pharmaceuticals, Inc. has a market capitalization of $0.43 billion, making it a small-cap company.
Does LXRX pay dividends?
No, Lexicon Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADCT
ADC Therapeutics S.A.
$3.73
Mkt Cap: $0.4B
BCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
CMPX
Compass Therapeutics, Inc.
$4.99
Mkt Cap: $0.7B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
FULC
Fulcrum Therapeutics, Inc.
$12.28
Mkt Cap: $0.7B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
OMER
Omeros Corporation
$9.60
Mkt Cap: $0.7B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
Explore stocks similar to LXRX for comparison